High-grade gliomas, metastases, and primary central nervous system lymphoma (PCNSL) are common high-grade brain lesions, which may have overlapping features on magnetic resonance (MR) imaging. Our objective was to assess the utility of 18-fluoride-fluoro-ethyl-tyrosine positron emission tomography (FET-PET) in reliably differentiating between these lesions, by studying their metabolic characteristics. Patients with high-grade brain lesions suspicious for glioma, with overlapping features for metastases and PCNSL were referred for FET-PET by Neuroradiologists from Multidisciplinary Neuro-Oncology Joint Clinic. Tumor-to-contralateral white mater ratio (T/Wm) at 5 and 20 min was derived and compared to histopathology. Receiver operating characteristic curve analysis was used to find the optimal T/Wm cutoff to differentiate between the tumor types. T/Wm was higher for glial tumors compared to nonglial tumors (metastases, PCNSL, tuberculoma, and anaplastic meningioma). A cutoff of 1.9 was derived to reliably diagnose a tumor of glial origin with a sensitivity and specificity of 93.8% and 91%, respectively. FET-PET can be used to diagnose glial tumors presenting as high-grade brain lesions when MR findings show overlapping features for other common high-grade lesions.
INTRODUCTION

Contrast-enhanced magnetic resonance imaging (MRI)
is the diagnostic modality of choice for characterizing brain neoplasms. [1] High-grade gliomas (HGGs), brain metastases (BM), and primary central nervous system lymphomas (PSNCL) are common high-grade brain malignancies in adults. [2] Contrast enhancement on T1-weighted images reflects areas of blood-brain barrier breakdown regardless of the pathology. [3] Advanced MR sequences, such as diffusion-weighted and perfusion imaging, are helpful; however, there still remains a subset of patients with imaging overlap. [4] Accurate preoperative diagnosis is often crucial because the management and prognosis of these tumors are substantially different. 18F-fluoroethyl-tyrosine (FET) is transported through L-amino acid transporters (LAT), which are present in normal brain parenchyma; and their expression proportionately increases with grade of glial proliferation. [5] It has been, thereby accepted as standard-of-care for differentiating between high-grade and low-grade glial tumors. [6] Since all three conditions mentioned above have altogether different management plans, there is an unmet need for a noninvasive modality for differentiating between these lesions. FET-positron-emission tomography (FET-PET) has the potential to specifically detect glial tumors using semi-quantitative parameters; [7] hence, we
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tumors -2016 were defined as "high grade") on index MRI, between October 2016 and October 2017, which showed overlapping features for HGG and metastases, HGG and PCNSL, or for all the three tumor types [ Positron-emission tomography imaging 18F-FET was manufactured at in-house medical cyclotron facility. PET studies were acquired after intravenous injection of 222-296 MBq of 18F-FET using dedicated PET/computed tomography (CT) scanners (Philips Astonish Time-of-Flight systems) incorporating 16-slice and 64-slice CT components, respectively. Static acquisition was performed by acquiring limited images with brain in field-of-view at 5 min and 20 min, each for the duration of 5 min.
Image processing
Images were processed and reported by one nuclear medicine physician who was blinded to clinical history and MR findings. Tumor-to-contralateral white mater ratio (T/Wm) was the semi-quantitative parameter used for image analysis. Transaxial slices showing the highest 18F-FET accumulation in the tumors were chosen for the region of interest (ROI) analyses. Three-dimensional volumetric ROI was placed on axial, coronal, and sagittal planes by the nuclear medicine physician [ Figure 1 ]. Maximum standardized uptake value (SUV max ) at the tumor site was derived. Another ROI was placed over contralateral white mater over three consecutive slices, and average of these values was taken as SUV max over contralateral white mater. T/Wm was calculated by dividing the above two parameters (SUV max of tumor and contralateral white mater). All primary brain lesions were subjected to a surgical biopsy or resection for histopathological confirmation. Receiver operating characteristic curve analysis was used to find the optimal T/Wm value that could differentiate glial tumors from other pathologies. Table 1 shows the demographic details, MR findings, FET-PET findings, and histopathological results in all patients. This study included 27 patients (male/female: 17/10), with a median conceptualized this study to generate reliable cut-off values by comparing the imaging findings with pathology.
RESULTS
MATERIALS AND METHODS
Patients
In this retrospective study design, we included 27 patients [ 
DISCUSSION
PCNSL, metastases, and HGG are the three most common differentials for high-grade intracranial lesions seen in clinical practice. Accurate differentiation is of high value as the management protocols and prognosis for each of three conditions is altogether different. [8] [9] [10] The objective of this study, therefore, was to assess the utility of FET-PET in detecting HGGs, when lesions did not demonstrate classical MRI features, in spite of high index of suspicion. Since we included just those patients who had equivocal MRI studies in spite of advanced sequences, the sample size was limited to 27 patients. We generated a cutoff of 1.9 for tumor-to-white matter ratio on FET-PET to distinguish between glial and nonglial lesions. Nonglial lesions included BM, PCNSL, two tuberculomas, and one anaplastic meningioma. Out of four patients with BM, two had primary in the lung, one as anorectal melanoma, and one in the breast. FET-PET, with a sensitivity and specificity of 93% and 91%, respectively, for diagnosing HGGs, has shown potential to be used in this clinical situation.
A meta-analysis by Dunet et al., [11] derived maximum tumor-to-background ratio (TBRmax) cutoff of 2.1 for differentiating glial and nonglial tumors. However, it had a modest sensitivity and specificity of 71% and 72%, primarily because gliomas across all grades were included in the study. Most studies using FET-PET have focused on its utility in grading gliomas. [12] Conventional MRI has similar accuracy, [13] for this purpose and recent literature with advanced magnetic resonance (MR) techniques have shown higher accuracy and specificity. [14] This obviates the need for additional molecular imaging for grading of gliomas. However, for undiagnosed brain lesions, MR features are not always confirmatory. MRI findings of tumor infiltration and contrast enhancement can be seen in all three high-grade tumors. Diffusion-weighted imaging which is an index of cellularity of tumor may be nonspecific in some cases. [15] Relative cerebral blood volume, a parameter on MR perfusion imaging, which offers the highest accuracy for distinguishing glioblastoma, metastases, and PCNSLs, [16] has remarkable sensitivity but has modest specificity of 64%. [17] There have been studies with fluorodeoxyglucose (FDG) PET for characterizing high-grade lesions. Purandare et al. showed no difference in SUV max values for HGG and BM whereas SUV max of 15.5 showed sensitivity and specificity of 84% and 80% for diagnosing PCNSL. [18] Two similar studies have shown the similar cutoff for detecting PCNSL, but false positives have been reported, owing to lack of specificity. [19, 20] The need of specific tracer is important since not all lesions are amenable to biopsy, and treatment plans are based on imaging diagnosis. Radiolabeled amino acids such as methionine and FET show selectively high uptake in proliferating glial tissue but low uptake in normal brain tissue. FET uptake significantly correlates with tumor cell density and proliferation rate as well as with microvascular density and neoangiogenesis; all of these being pathological markers of HGGs. [21] FET is not incorporated into metabolic pathway, and uptake is directly proportional to the density of LAT-2; which is overexpressed on proliferating glial cells and not present on inflammatory cell or other tumor types, making it specific for HGGs. FET localization is independent of the integrity of blood-brain barrier, thus nonenhancing lesions on MR can be characterized. [22] Another important aspect is the impact of steroid on the uptake of FET. Unlike FDG-PET, in which uptake could be influenced by cumulative doses of corticosteroid before a PET scan, steroids do not significantly impact TBR values in FET-PET. [23, 24] Unlike existing literature that proposes a dynamic imaging protocol, we preferred dual-point static acquisition (5 and 20 min), based on the study by Albert et al. [25] Peak FET concentration in glial tumors occurs approximately at 20 min and declines slightly thereafter. 5-min image was acquired to assess the tumor perfusion, which shows an early peak in HGGs, with a small subset of lesions showing overestimation of FET uptake in early images due to high vascularity. [26] Static 20-min image helps to confirm the findings on 5-min image as well as provides tumor extent. In addition, static acquisition improved patient compliance with shorter scanning time, avoiding motion artifacts. It led to reduction of scanning time per patient, which is crucial for high-volume PET/ CT departments.
Rapp et al. [27] derived a TBRmax cutoff of 2.5 to differentiate gliomas from other brain lesions. However, the clinical benefit was unclear as it included all brain lesions, including high-and low-grade gliomas, which brought down the sensitivity to 57%. Since molecular imaging using PET involves target-specific tracers, the clinical question that is to be answered is of utmost importance. Our study was thereby designed to address a practical clinical issue faced in neuro-oncology clinic of a large tertiary care hospital. The retrospective nature and small cohort are the limitations; however, with the results of this study, a larger prospective study can be designed to generate more robust results.
CONCLUSION
FET-PET has shown potential to become the modality of choice for detecting high-grade glial tumors from other high-grade brain lesions when the MRI features are equivocal. 
